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OBJECTIVE Transcranial magnetic resonance–guided focused ultrasound surgery (tcMRgFUS) is one of the emerging 
noninvasive technologies for the treatment of neurological disorders such as essential tremor (ET), idiopathic asym-
metrical tremor-dominant Parkinson’s disease (PD), and neuropathic pain. In this clinical series the authors present the 
preliminary results achieved with the world’s first tcMRgFUS system integrated with a 1.5-T MRI unit.
METHODS The authors describe the results of tcMRgFUS in a sample of patients with ET and with PD who underwent 
the procedure during the period from January 2015 to September 2017. A monolateral ventralis intermedius nucleus 
(VIM) thalamic ablation was performed in both ET and PD patients. In all the tcMRgFUS treatments, a 1.5-T MRI scan-
ner was used for both planning and monitoring the procedure.
RESULTS During the study period, a total of 26 patients underwent tcMRgFUS thalamic ablation for different move-
ment disorders. Among these patients, 18 were diagnosed with ET and 4 were affected by PD. All patients with PD 
were treated using tcMRgFUS thalamic ablation and all completed the procedure. Among the 18 patients with ET, 13 
successfully underwent tcMRgFUS, 4 aborted the procedure during ultrasound delivery, and 1 did not undergo the 
tcMRgFUS procedure after stereotactic frame placement. Two patients with ET were not included in the results because 
of the short follow-up duration at the time of this study. A monolateral VIM thalamic ablation in both ET and PD patients 
was performed. All the enrolled patients were evaluated before the treatment and 2 days after, with a clinical control of 
the treatment effectiveness using the graphic items of the Fahn-Tolosa-Marin tremor rating scale. A global reevaluation 
was performed 3 months (17/22 patients) and 6 months (11/22 patients) after the treatment; the reevaluation consisted 
of clinical questionnaires, neurological tests, and video recordings of the tests. All the ET and PD treated patients who 
completed the procedure showed an immediate amelioration of tremor severity, with no intra- or posttreatment severe 
permanent side effects.
CONCLUSIONS Although this study reports on a small number of patients with a short follow-up duration, the 
tcMRgFUS procedure using a 1.5-T MRI unit resulted in a safe and effective treatment option for motor symptoms in 
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In the recent past, surgical stereotactic lesioning of the thalamus and basal ganglia has been used for the treat-ment of different cerebral functional disorders. In this 
setting, magnetic resonance–guided focused ultrasound 
surgery (MRgFUS) has emerged as a noninvasive thermal 
ablation method, which uses high-intensity focused ultra-
sound (HI-FU) energy and MRI for anatomical imaging 
and real-time thermal mapping.48 Thanks to this novel 
technology, today it is possible to obtain a rigorous focal 
point within the planned target and across the intact skull 
for the treatment of neurological disorders.6,7,13,36,43
The HI-FU adopted in MRgFUS generates its effects 
on target tissues through several mechanisms: direct heat-
ing, cavitation, and shear stress.52 Since its development, 
the most recent technologies have allowed the use of HI-
FU in neurosurgical practice.1,21,28,30,31,52 MRI guidance is 
used for both the planning and the thermal monitoring of 
the targeted area, thanks to water proton resonance fre-
quency–shift thermometry.30,35
At the beginning, MRgFUS was used to treat both be-
nign and malignant neoplasms.24,27,49 Currently, this pro-
cedure is being used for new clinical and experimental 
scenarios.3,14,15,35 In functional neurosurgery, transcranial 
MRgFUS (tcMRgFUS) is definitely emerging as a non-
invasive, nonprosthetic, guided, and repeatable technique 
for treating mostly idiopathic tremor–dominant Parkin-
son’s disease (PD), essential tremor (ET), and neuropathic 
pain.1,11,36,51
ET and PD are neurological disorders with a high prev-
alence. The history of their pathological progression leads 
to drug resistance and to the decline of quality of life.8,16, 
20,26 In this clinical series we aim to present the results ob-
tained by treating tremor in patients suffering from ET 
and PD with the world’s first tcMRgFUS system integrat-
ed with a 1.5-T MRI unit.
Methods
Patients and Study Criteria
From January 2015 to September 2017 at the University 
Hospital “Paolo Giaccone” of Palermo, Italy, 26 patients 
underwent tcMRgFUS thalamic ablation for different 
functional and movement disorders: 20 patients suffered 
from ET, 4 patients suffered from PD, 1 patient suffered 
from neuropathic pain, and 1 patient suffered from in-
tentional tremor secondary to multiple sclerosis (MS). 
Among these 26 patients, only 23 were enrolled in this 
study: 18 with ET, 4 with PD, and the 1 patient with MS 
(Table 1). The patient with MS was not treated because of 
a sudden laryngospasm while she was lying on the MRI 
machine, before the sonications were performed. The 4 
patients with PD (4 men, mean age 68 ± 4.74 years) were 
all treated by tcMRgFUS thalamic ablation and complet-
ed the procedure. Among the 18 patients with ET (13 men, 
5 women, mean age 65 ± 13.02 years), 13 successfully un-
derwent tcMRgFUS (10 men, 3 women, mean age 65.22 
± 11.87 years), 4 aborted the procedure during ultrasound 
delivery, and 1 did not undergo tcMRgFUS after stereo-
tactic frame placement. Two patients with ET were not 
considered for treatment because of a short follow-up du-
ration at the time of manuscript submission. The patients 
who completed the procedure were treated by monolateral 
tcMRgFUS ventralis intermedius nucleus (VIM) thalamic 
ablation both in cases of ET and in cases of PD.
Eligibility criteria were age between 18 and 80 years, 
patient ability to give informed consent and undergo 
clinical evaluations, the possibility of performing CT and 
MRI, and a proper skull density ratio. In both ET and PD 
patients, tremor had to be confirmed by a movement dis-
order–skilled neurologist, be resistant to a stable dose of 
medications, and cause substantial disability in daily life. 
The interruption of pharmacological therapy before the 
treatment, because of its inefficiency, was not considered 
an exclusion criterion. Every patient who did not meet 
such eligibility criteria, suffered from psychiatric illness, 
presented a risk of bleeding, had neurological and car-
diovascular comorbidities, had dermatological illness on 
the scalp, or had a standard contraindication to CT/MRI 
was excluded from the treatment. Demographic data are 
shown in Table 1.
Outcome Evaluation
All enrolled patients were evaluated before the treat-
ment (baseline). The follow-up evaluations were per-
formed 2 days and then 3 (17/22 patients) and 6 months 
(11/22 patients) after the treatment. These evaluations con-
sisted of clinical questionnaires, neurological tests, and 
video recordings of the tests.
Tremor severity was evaluated by the neurosurgeons 
using the Fahn-Tolosa-Marin (FTM) tremor rating scale 
in the patients with ET, and the third section of the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) in the 4 
patients with PD.
For the purpose of this study, only the scores obtained 
from patients who completed the tcMRgFUS procedure 
were considered and analyzed. For each patient with ET, 
the global FTM score (range 0–144) was assessed before 
treatment and at the 3- and 6-month follow-up evalua-
tions; the second section of the FTM scale (graphic ability, 
range 0–16) for the contralateral hand was also evaluated 
on the 2nd day after the treatment to assess the immediate 
improvement in graphic abilities.
All the patients with ET enrolled in this series were 
patients with ET and PD. To the best of the authors’ knowledge, this is the first clinical series in which thalamotomy was 
performed using tcMRgFUS integrated with a 1.5-T magnet.
https://thejns.org/doi/abs/10.3171/2017.11.FOCUS17614
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also evaluated with the Quality of Life in Essential Tremor 
(QUEST) questionnaire at baseline and at 3- and 6-month 
follow-up evaluations to assess their quality of life (range 
0%–100%, in which 100% is the greatest perceived dis-
ability and the worst quality of life).
For each patient with PD, the third section of the 
UPDRS was assessed before the treatment (baseline) and 
at 3 months. No evaluation at 6 months has been per-
formed yet.
Patients underwent neurological assessment before and 
after each treatment. Moreover, after each sonication, the 
tremor and its amelioration were assessed by a clinical 
evaluation and drawing tests.
Brain screening and follow-up MRI were performed 
with a Signa HDxt 1.5-T unit (GE Medical Systems) using 
an 8-channel phased-array head coil. The MRI conven-
tional protocol used for screenings and follow-up evalua-
tions included 2D axial fast spin echo (FSE) T1- and T2-
weighted pulse sequences, sagittal T2-weighted 3D CUBE 
FLAIR with fat saturation, sagittal 3D T1-weighted fast 
spoiled gradient echo (FSPGR), and axial 3D susceptibil-
ity-weighted angiography (SWAN; 3-mm thickness). The 
tcMRgFUS specific planning protocol included sagittal, 
coronal, and axial high-resolution (2-mm-thick/no gap) 
T2-weighted fast recalled FSE (FRFSE). The same plan-
ning sequences were used for live MRI during the treat-
ments, using a dedicated 2-channel head coil. CT brain 
scans were acquired using a 16-channel multidetector CT 
unit (BrightSpeed, GE Medical Systems) with the follow-
ing parameters: tube voltage 120 kV, tube current 220 mA, 
pure axial plane (0° gantry tilting), sequential acquisition, 
1.25-mm slice thickness, and bone kernel.
tcMRgFUS Thalamotomy Procedure
This tcMRgFUS system (ExAblate 4000, InSightec 
Ltd.) consists of a hemispheric 1024-element phased-ar-
ray transducer operating at 650 kHz, similar to those used 
with 3.0-T MRI units.7
Before the procedure, the patient’s scalp was shaved 
and fixed with the stereotactic frame (Fig. 1A), and a seal-
ant membrane with the embedded dedicated coil was posi-
tioned on the head of the patient (Fig. 1B). Once the frame 
was locked to the helmet, the helmet itself was filled with 
degassed circulating cooled water for an optimal coupling 
and to avoid any heat damage to the skin and to the skull. 
During the treatment, the patient and both the monitoring 
and the operating physicians had access to an emergency 
stop sonication button. Patient vital signs were constantly 
monitored during each procedure.
Target position was calculated on MR images by ca-
nonical stereotaxic coordinates: 75% of the intercommis-
sural line (anterior commissure–posterior commissure 
TABLE 1. Demographic data of enrolled patients
Case  
No.
Age (yrs),  
Sex Disorder
Disease  
Duration (yrs) tcMRgFUS Therapy at Treatment
Treated  
Hand
FU  
(mos)
1 45, M ET 45 Completed Gabapentin, clonazepam, delorazepam, domperidone Rt 6
2 70, M ET 4 Completed Pregabalin, duloxetine Rt 6
3 75, F ET 15 Completed Propranolol Rt 6
4 77, M ET 25 Completed Suspended before treatment due to inefficacy Rt 6
5 35, M ET 10 Completed Mirtazapine, delorazepam Lt 6
6 75, F ET 70 Completed Clonazepam, pregabalin, duloxetine, trazodone Rt 6
7 67, M ET 3 Completed Primidone Rt 6
8 75, M ET 20 Completed Propranolol Rt 6
9 53, M ET 5 Completed Propranolol, clonazepam Rt 3
10 71, M ET 63 Completed Bromazepam, primidone Rt 6
11 72, M ET 6 Completed Suspended before treatment due to inefficacy Rt 3
12 55, M ET 10 Completed Propranolol Rt 6
13 75, F ET 15 Completed Primidone Rt 6
14 70, F ET 10 Aborted (severe HA) Delorazepam Rt Aborted
15 71, M ET 21 Aborted (severe HA) Suspended before treatment due to inefficacy Rt Aborted
16 50, M ET 25 Aborted (severe HA) Primidone Rt Aborted
17 66, M ET 20 Aborted (low temp) Propranolol, primidone Rt Aborted
18 72, F ET 22 NP (TIA) Suspended before treatment due to inefficacy NP NP
19 52, F MS 5 NP (laryngospasm) Paroxetine, baclofen NP NP
20 61, M PD 14 Completed Levodopa, carbidopa, quetiapine, pregabalin Rt 3
21 74, M PD 30 Completed Melevodopa, carbidopa, pramipexole Rt 3
22 67, M PD 6 Completed Levodopa, carbidopa, oxybutynin Rt 3
23 70, M PD 6 Completed Levodopa, carbidopa, pramipexole, amitriptyline Rt 3
FU = follow-up; HA = headache; NP = not performed; temp = temperature; TIA = transient ischemic attack.
The right hand was the tremor-dominant hand in all patients.
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line), 12–14 mm laterally from the median plane, and 0–2 
mm caudocranially from the intercommissural plane. For 
each patient, the treatment was planned by registering the 
CT and MRI images, marking as “no pass” regions any 
calcifications and other critical regions that could affect 
the HI-FU path. The number of transducer elements that 
had to be employed (should not be < 700) and the actual 
head surface (should not be < 250 cm2) available for the 
energy required to be delivered were thus calculated. Fi-
ducial markers were placed on live MR images to enable 
automatic movement detection.
Before starting the procedure, a tracking scan was run 
to verify and register the transducer home position, and 
the central MRI frequency was verified. The transducer’s 
focal point and the MRI system alignment in all 3 axes 
were verified before the actual treatment by perform-
ing short (10-second) low-energy sonications (≤ 250 W). 
The HI-FU beam power was then gradually increased to 
FIG. 1. Images showing patient preparation for tcMRgFUS. A: Stereotactic frame positioning. B: Patient sitting on the dedicated 
MRI table with the stereotactic frame fixed and the silicon sealant membrane already positioned; 1 of the 2 rings of the dedicated 
coil is clearly visible on the left side of the patient’s head.
FIG. 2. ExAblate Neuro workstation and treatment plan.
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achieve temperatures in the range of 50°–54°C that will 
result in a transient clinical effect. Once the optimal target 
was confirmed, and no side effects were reported by the 
patient, a further increase in the HI-FU beam power was 
used to achieve higher temperatures (≥ 55°C) to obtain a 
permanent lesioning of the targeted volume (Fig. 2).44
At the end of each cluster of lesioning sonications, 
high-resolution T2-weighted sequences were acquired by 
the dedicated 2-channel head coil to visualize the result-
ing thalamic lesion. Neither steroid treatment nor osmotic 
drugs were administered after the treatments.
Results
For all 13 patients with ET and 4 patients with PD who 
completed the tcMRgFUS procedure, the thalamic VIM 
was chosen as the target. In 17 patients the left VIM was 
ablated, which was contralateral to the dominant hand, in 
both ET and PD cases. The right VIM was ablated in only 
1 patient, which was contralateral from the onset of the 
tremor, to effectively treat an axial tremor.
Tremor
All the ET and PD treated patients who completed the 
procedure did show a substantial and immediate improve-
ment in graphical and neurological tests. A subjective im-
provement of axial and voice tremor was also reported by 
the patients with ET who suffered from this symptomatol-
ogy.
At baseline, the FTM global score for all the treated pa-
tients with ET showed a mean value of 40.2 ± 11.8 (range 
15–63) and the second section of the FTM reported a 
mean hand tremor score of 6.4 ± 2.97 (range 3–13). Two 
days after the treatment, a meaningful 66.4% reduction of 
tremor was reported by the second section of the FTM, 
with a mean value of 2.15 ± 0.86 (range 1–3). No improve-
ment was shown in the ipsilateral side of the body to the 
treated thalamus.
All the patients underwent the 3-month follow-up evalu-
ation, while the 6-month evaluation was performed only in 
11 patients with ET. At the 3-month follow-up, a meaning-
ful reduction of 57% of the global tremor was reported by 
the FTM, from a mean baseline value of 40.2 ± 11.8 to 
17.3 ± 7.31. In these patients, an improvement of 51% in 
their quality of life was reported by the QUEST, from a 
mean baseline value of 35.09 ± 12.25 to a mean value of 
17.09 ± 10.67 at 3 months. In the 11 patients who also un-
derwent the 6-month follow-up, a meaningful reduction of 
58% of the global tremor was reported by the FTM, from 
a mean baseline of 41.73 ± 9.93 to 17.73 ± 8.80, and an 
improvement of 46% in their quality of life, from a mean 
baseline of 34.03 ± 12.9 to a mean value of 18.44 ± 13.76. 
An improvement in the graphic ability tests was also docu-
mented. All these results will be reevaluated in a longer 
follow-up (Table 2).
Concerning the 4 treated patients with PD, a significant 
improvement of 52% of the tremor was achieved, from a 
mean tremor score of 36.5 ± 12.54 at baseline to a mean 
tremor score of 17.5 ± 5.5 at the 3-month follow-up ac-
cording to the third section of the UPDRS. All of the pa-
tients with PD had not reached the 6-month follow-up at 
the time of submission of this manuscript (Table 3).
TABLE 2. Follow-up overview of patients with ET who underwent successful tcMRgFUS
Case 
No.
Hand Score (graphic ability) Global FTM Score QUEST Score
Baseline 2 Days 3 Mos 6 Mos Baseline 3 Mos 6 Mos Baseline 3 Mos 6 Mos
1 3 1 2 6 44 22 29 50 20.19 35
2 5 3 2 0 27 14 17 35.83 6.73 10.83
3 4 1 1 1 63 17 16 56.9 20 20
4 4 1 1 0 37 10 8 9.61 2.77 2.83
5 6 3 2 1 37 13 10 29.17 10.83 9.80
6 6 2 1 1 43 14 12 50 27 27.88
7 13 3 3 2 49 20 17 27 2.77 2.88
8 12 3 5 6 54 37 40 26.85 40.38 49
9 3 1 1 In FU 15 9 In FU 36.66 20.19 In FU
10 8 3 3 3 33 17 18 28.84 20.19 24.04
11 7 3 3 In FU 49 26 In FU 45.09 29.8 In FU
12 6 2 1 2 39 14 14 26.85 9.61 9.8
13 6 2 2 2 33 12 13 33.33 11.76 10.78
Mean 6.4 2.2 2.1 2.2 40.2 17.3 17.7 35.09 17.09 18.44
TABLE 3. Follow-up overview of patients with PD who underwent 
successful tcMRgFUS
Case No.
UPDRS Score*
Baseline 3 Mos
20 20 11
21 38 18
22 33 15
23 55 26
Mean 36.5 17.5
All patients are currently in follow-up at the 6-month interval.
* Third section of the UPDRS.
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Adverse Events
Among the 18 patients with ET enrolled in this study, 5 
did not complete the tcMRgFUS procedure. In 4 of them 
the procedure was aborted because of a sudden and in-
tense remitting headache related to the HI-FU delivery. In 
the last patient, the procedure was aborted after several 
sonications because of the failure in reaching a sufficient 
temperature to perform ultrasonic thalamic ablation, due 
to the patient’s skull thickness and density ratio.12 The pro-
cedure was voided in a single enrolled patient, who did not 
undergo any sonication because of a severe blood pres-
sure increase, which led to a transient ischemic attack re-
lated to a stress response of the patient to the stereotactic 
frame placement. The patient was medically treated and 
monitored in a semi-intensive care unit until the symptoms 
faded in a few hours.
Among the 13 ET and 4 PD patients enrolled and treat-
ed, 2 showed temporary paresthesias to the contralateral 
hand. One patient showed temporary weakness in grip to 
the treated hand, which faded in about a week. Four pa-
tients showed gait disturbance after the thalamotomy: in 
2 of them ataxia completely faded within the time of dis-
charge; in another patient ataxia partially improved within 
the time of discharge and had completely disappeared at 3 
months’ follow-up; in the last patient, ataxia was noticed 
during the entire 6 months of follow-up. Two patients re-
ported a subjective loss of balance; in 1 of these patients it 
lasted for the entire follow-up period.
In a self-assessment test performed on the 2nd day after 
the treatment, no patient complained about any moderate 
or severe disability or any other generic symptoms. Most 
of the patients reported tiredness, often referring to the 
hospitalization itself. In only a few patients a slight weak-
ness on the contralateral side of the body was reported.
Regarding the stereotactic frame placement, 3 patients 
showed temporary headache after the frame removal: 1 
patient showed a temporary scalp numbness, which faded 
in about 24 hours, and 1 patient reported a skin wound 
due to the placement of the pin of the frame. In a single 
patient, a minor displacement of the stereotactic frame was 
reported during the last stages of the treatment, which was 
corrected by electronic steering only.
During HI-FU delivery, 4 patients complained of dizzi-
ness and paroxysmal vertigo. One patient reported a feel-
ing of water flushing around the head even after the frame 
removal, and a single patient experienced a subjective pos-
tural instability leaving the MRI table. No major adverse 
event was noted.
Neuroradiological Evaluation
T2-weighted MRI sequences acquired at the end of 
each treatment showed the resulting thalamotomy as a 
hyperintense round-shaped lesion with a variable amount 
of perilesional vasogenic edema. Every treated patient un-
derwent brain MRI 48 hours after the treatment with the 
reported protocol (Fig. 3). At this time, on T2-weighted 
pulse sequences, VIM lesions showed the typical imaging 
findings with 3 typical concentric zones:56 a central dark 
spot (not always clearly appreciable) with a strongly hyper-
intense peripheral zone demarcated by a hypointense rim 
and a slightly hyperintense zone of perilesional vasogenic 
edema (Fig. 3A). The lesion itself showed a true restriction 
of water molecule movements on apparent diffusion co-
efficient maps (Fig. 3D). Susceptibility-weighted imaging 
showed blood products within the core of the lesions (Figs. 
FIG. 3. Posttreatment (48-hour) neuroradiological assessment: axial 
samples from the MRI protocol used for both screenings and follow-ups 
using a standard 8-channel phased-array head coil (detail of the basal 
ganglia region). A: T2-weighted FSE (5-mm thickness) showing the 
thalamic lesion and the reversible perilesional vasogenic edema spread-
ing laterally among the white matter bundles of the posterior limb of the 
internal capsule up to the medial edge of the globus pallidus.  B: Min-
imum-intensity projection (3-mm thickness) from the axial 3D SWAN 
sequence showing intralesional blood products as hypointense spots.  
C and D: Echo planar diffusion-weighted imaging (5-mm thickness; C) 
acquired using b values of 0 and 1000 sec/mm2 and related apparent 
diffusion coefficient map (D) revealing true restriction of water molecule 
motion due to coagulation necrosis and protein precipitation. E: Mul-
tiplanar reconstruction (3-mm thickness) from the sagittal 3D FLAIR 
fat-saturated sequence at the same level is less useful for differentiating 
lesion margins from perilesional tissue compared with T2-weighted FSE 
sequences. F: Multiplanar reconstruction (3-mm thickness) using an 
average algorithm from the sagittal 3D FSPGR sequence showing focal 
areas of T1 shortening due to persistent blood-brain barrier leaks.
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3B and 4). At the 48-hour follow-up MRI, all the lesions 
had almost doubled in size and the amount of perilesional 
vasogenic edema had increased. On subsequent follow-up 
images lesion size shrank, until they almost disappeared 
on T2-weighted pulse sequences after 6–9 months (Fig. 4). 
In some cases, small spots of blood-brain barrier (BBB) 
leaks were still appreciable at the 48-hour MRI follow-
up (Fig. 3F), but never on subsequent MRI follow-ups. 
Susceptibility-weighted imaging revealed the presence of 
hypointense intralesional blood products (hemosiderin) on 
all follow-up MRI examinations despite the normalization 
of other MRI findings on conventional pulse sequences 
(Fig. 4).
Discussion
In this clinical series in which 13 ET and 4 hyperkinetic 
PD patients were evaluated, thalamic VIM ablation was 
performed by tcMRgFUS. The data obtained did show an 
amelioration of contralateral tremor, as demonstrated by 
the results from graphical tests and the FTM. Moreover, a 
significant quality of life improvement was shown, as as-
sessed by the QUEST questionnaire.
To the best of our knowledge, this is the first series of 
patients treated with a tcMRgFUS system integrated with 
a 1.5-T unit. In this method, tcMRgFUS thalamotomy 
emerges as a safe, effective, and noninvasive technique in 
treating specific movement disorders, even using the most 
common and affordable 1.5-T MRI machines. In addition, 
tcMRgFUS thalamotomy allows a monolateral treatment, 
compared with traditional deep brain stimulation, but with 
shorter durations and fewer surgical risks.
The first clinical study of tcMRgFUS feasibility began 
in 2008 for the treatment of drug-resistant thalamic neuro-
pathic pain.32 Further studies about the treatment of behav-
ioral disorders have already been published.38
Regarding movement disorder treatment, the study of 
Elias et al. performed in 2013 demonstrated the effective 
thalamic VIM ablation through tcMRgFUS in a popula-
tion of 15 drug-resistant patients with ET. In that series, a 
significant improvement of tremor and quality of life was 
obtained after 1 year of follow-up.17 The randomized trial 
that followed that series in 2016 confirmed the effective-
ness of tcMRgFUS in 67 patients with ET compared with 
the sham procedure.18 In this trial, an amelioration of hand 
tremor from 18.1 to 9.6 points was found. In 2013, a second 
preliminary study about ET treatment through tcMRgFUS 
confirmed the effectiveness of this technique.41 In the same 
year, positive results were obtained from the tcMRgFUS 
treatment of 8 patients with PD, with an improvement of 
57.1% at 3 months in the UPDRS evaluation; these results 
were confirmed in 2014 by a significant UPDRS improve-
ment.42
In all the reported series, tcMRgFUS treatments were 
performed using 3-T MRI machines (Table 4). These units 
guarantee a greater spatial and contrast resolution but do 
not guarantee the same safety profile as 1.5-T MRI ma-
chines.33 Moreover, compared with 1.5-T magnets, 3-T 
magnets also suffer from higher susceptibility and dielec-
tric artifacts that could severely influence imaging qual-
ity during tcMRgFUS treatments. Our preliminary results 
demonstrated the safety and the diagnostic and therapeu-
tic effectiveness of a 1.5-T MRI machine for tcMRgFUS 
treatments.22,29 Regarding effectiveness, no difficulty or 
error in targeting was encountered and the targeting accu-
racy was confirmed by the clinical results. Moreover, the 
feasibility and effectiveness of tcMRgFUS performed with 
an affordable 1.5-T unit establishes the path to wider use of 
this emerging technique around the world, because 1.5-T 
MRI machines are widely installed worldwide and require 
lower purchase, installation, and maintenance costs.
For a long time, movement disorders and neuropathic 
pain have been treated with radiofrequency ablation, deep 
brain stimulation, or stereotactic radiosurgery. Unfortu-
nately, these techniques are burdened by a high rate of ad-
FIG. 4. Axial high-resolution FRFSE (A–D) and axial 3D SWAN (E–H) 
at different time points: screening MRI (t0, A and E), 2 days (t48h, B and 
F), 3 months (t3m, C and G), and 6 months (t6m, D and H). The natural 
evolution of the therapeutic lesion is shown on T2-weighted FSE despite 
the persistence of blood product deposits even on later follow-up evalu-
ations.
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verse events and surgical risks, with possible permanent 
neurological dysfunctions.10,17 Thanks to its noninvasive-
ness, tcMRgFUS avoids the risk of infection, lowers the 
risk of bleeding, and reduces adverse effects and damage 
to the tissues surrounding the target. Also, tcMRgFUS al-
lows clinical outcomes similar to those of radiofrequency 
ablation thalamotomy or deep brain stimulation,40,53 and 
it also permits one to obtain an immediate and verifiable 
lesion.11 It does not use ionizing radiation and it is a non-
invasive technique; moreover, patient feedback allows the 
physician to optimize the target before a permanent lesion 
is made, because the clinical effect can be evaluated im-
mediately during each sonication. Furthermore, the use of 
MRI as a guidance for the HI-FU beam allows a precise 
real-time location of the target volume, the establishment 
of precise safety margins, and a real-time temperature 
control.32 Lastly, it may be feasible to more easily consider 
re-treatment as an option in those cases in which tremor 
may return.
The profile of adverse events related to tcMRgFUS 
treatment appears to be similar to the profile of radiofre-
quency ablation thalamotomy, mainly due to wrong posi-
tioning or larger target volume.41 However, these risks are 
limited in tcMRgFUS treatment because it is a noninva-
sive technique that does not harm skull or brain parenchy-
ma through probe insertion or because of uncontrollable 
lesion development. Interestingly, a progressive decrease 
in lesion volume has been shown in the long term after the 
tcMRgFUS procedure. In contrast, radiofrequency abla-
tion lesions are less spatially controllable, and the Gamma 
Knife radiosurgical treatment creates lesions that may 
keep growing over time, with the possible occurrence of 
progressive neurological deficits.39
Future Perspectives in tcMRgFUS
The feasibility of bilateral tcMRgFUS thalamotomy 
remains a matter of debate because of the high risk of ad-
verse events in cases of permanent lesioning, in particular 
ataxia and speech disturbances.4,54 Despite this, promising 
results were obtained by Gallay and colleagues with bilat-
eral cerebellothalamic tractotomy through tcMRgFUS in 
a series of 18 patients with ET.23 Gallay et al.’s study envis-
ages the feasibility of bilateral lesioning without perma-
nent side effects, even if this has not yet been replicated.50
Several controlling technologies5 and applicable fields 
are now arising concerning new therapeutic perspectives of 
tcMRgFUS, such as neurooncological treatment,3,14,43 con-
trol of BBB permeability,9,44,45 controlled drug diffusion34,37 
and antiblastic therapy across the BBB,2,19,35,43,55 subcorti-
cal drug-resistant epilepsy, obstructive hydrocephalus and 
drug-resistant psychiatric disorders,46 intracranial throm-
bosis through sonothrombolysis,25 and trigeminal neural-
gia.47
Despite the obtained results, this clinical series suffers 
from some limitations. Both patients and physicians were 
aware of the treatment performed in this study; the pa-
tient sample is small, and the follow-up duration is ongo-
ing. Moreover, the present study lacks a control group, and 
therefore it has not been possible to evaluate the effective-
ness of tcMRgFUS thalamotomy compared with the other 
stereotactic procedures that have been performed for a 
long time. Despite these limitations, every patient showed 
a significant amelioration of tremor in the treated hand and 
of the motor function, as shown by results from the clinical 
tests conducted after treatment. In this way, tcMRgFUS is 
confirmed as a reliable choice in the treatment of motor 
disorders, with a high profile of safety and effectiveness, 
even using a 1.5-T MRI unit.
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